Clinical value of circulating lipocalins and insulin-like growth factor axis in pancreatic cancer diagnosis

Pancreas

Volumn 42, Issue 1, 2013, Pages 149-154

  El Mesallamy, Hala O ^a   Hamdy, Nadia M ^a   Zaghloul, Ashraf S ^b   Sallam, Alaliaa M ^a  

^a Ain Shams University   (Egypt)

^b NATIONAL CANCER INSTITUTE   (Egypt)

Author keywords

IGF I; insulin resistance; NGAL; pancreatic cancer; RBP 4

Indexed keywords

CA 19-9 ANTIGEN; INSULIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; RETINOL BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ACUTE-PHASE PROTEINS; AREA UNDER CURVE; BIOLOGICAL MARKERS; CA-19-9 ANTIGEN; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LIPOCALINS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RETINOL-BINDING PROTEINS, PLASMA; ROC CURVE; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84872083433     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182550d9d     Document Type: Article

References (30)

1. Saruc M, Karaarslan M, Rasa K, et al. Pancreatic cancer and glucose metabolism. Turk J Gastroenterol. 2009;20(4):257-260.
2. Dalamaga M, Migdalis I, Fargnoli J, et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control. 2009;20(5):625-633.
3. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134:95-101.
4. Pannala R, Basu A, Petersen GM, et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10:88-95.
5. Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer. 2011;47(13):1928-1937.
6. Yamaguchi K. How to define patients at high risk for pancreatic cancer. Pancreatology. 2011;11 (suppl 2):3-6.
7. Osório-Costa F, Rocha GZ, Dias D, et al. Epidemiological and molecular mechanisms aspects linking obesity and cancer. Arq Bras Endocrinol Metabol. 2009;53(2):213-226.
8. Godsland I. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci (Lond). 2010;118:315-332.
9. Lee J, Im J, Park K, et al. Retinol binding protein 4 and insulin resistance in apparently healthy elderly subjects. Clin Chim Acta. 2009;400:30-32.
10. Kowalska I, Straczkowski M, Adamska A, et al. Serum retinol binding protein 4 is related to insulin resistance and nonoxidative glucose metabolism in lean and obese women with normal glucose tolerance. J Clin Endocrinol Metab. 2008;93:2786-2789.
11. Esteve E, Ricart W, Real J. Adipocytokines and insulin resistance: the possible role of lipocalin-2, retinol binding protein-4, and adiponectin. Diabetes Care. 2009;32:S362-S367.
12. Wang Y, Lam K, Kraegen E, et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem. 2007;53:34-41.
13. Tong Z, Kunnumakkara A, Wang H, et al. Neutrophil gelatinaseYassociated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res. 2008;68(15): 6100-6108.
14. Moniaux N, Chakraborty S, Yalniz M, et al. Early diagnosis of pancreatic cancer: neutrophil gelatinaseYassociated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer. 2008;98:1540-1547.
15. Bartosch-Harlid A, Andersson R. Diabetes mellitus in pancreatic cancer and the need for diagnosis of asymptomatic disease. Pancreatology. 2010;10:423-428.
16. Kwon J, Stephan S, Mukhopadhyay A, et al. Insulin receptor substrate-2 mediated insulin-like growth factor-1 receptor overexpression in pancreatic adenocarcinoma through protein kinase CC. Cancer Res. 2009;69(4):1350-1357.
17. Wolpin B, Michaud D, Giovannucci E, et al. Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. Br J Cancer. 2007;97:98-104.
18. Azar M, Lyons T. Diabetes, insulin treatment, and cancer risk: what is the evidence? Med Rep. 2010;2:4.
19. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem. 1969;6:24-27.
20. Abraham E, Huff T, Cope N, et al. Determination of the glycosylated hemoglobins (HbA1) with a new microcolumn procedure. Suitability of the technique for assessing the clinical management of diabetes mellitus. Diabetes. 1978;27:931-937.
21. Matthews D, Hosker J, Rudenski A, et al. Homeostasis model assessment: insulin resistance and A-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
22. Stolzenberg-Solomon R, Graubard B, Chari S, et al. Insulin, glucose, insulin resistance and pancreatic cancer in male smokers. JAMA. 2005;294(22):2872-2878.
23. Uygur-Bayramiçli O, Dabak R, Orbay E, et al. Type 2 diabetes mellitus and CA 19-9 levels. World J Gastroenterol. 2007;13(40):5357-5359.
24. Zhang S, Wang YM, Sun CD, et al. Clinical value of serum CA19-9 levels in evaluating respectability of pancreatic carcinoma. World J Gastroenterol. 2008;14:3750-3753.
25. Bobbert P, Weitha?user A, Andres J, et al. Increased plasma retinol binding protein 4 levels in patients with inflammatory cardiomyopathy. Eur J Heart Fail. 2009;11(12):1163-1168.
26. Law I, Xu A, Lam K, et al. Lipocalin-2 deficiency attenuates insulin resistance associated with aging and obesity. Diabetes. 2010;59:4872-4882.
27. Tomizawa M, Shinozaki F, Sugiyama T, et al. Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer. World J Gastroenterol. 2010;16(15):1854-1858.
28. Talar-Wojnarowska R, Gasiorowska A, Olakowski M, et al. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis. Pancreatology. 2010;10:689-694.
29. Ulaneta D, Ludwigb D, Kahnc C, et al. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A. 2010; 107(24):10791-10798.
30. Horiguchi A, Ito K, Sumitomo M, et al. Decreased serum adiponectin levels in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol. 2008;38(2):106-111.